McKinsey delivered a mostly upbeat assessment of Europe’s biotechnology industry in August when it published a report titled, “Biotech in Europe: A Strong Foundation for Growth and Innovation.”
“European biotechs offer investors space for growth and momentum,” McKinsey concluded in its report. “With a strong science base that is less fully utilized than its U.S. counterpart, they have ample opportunities to translate innovation into products. Armed with adequate funding to expand, they could achieve global competitiveness and success in coming years.”
